Mayo Clinic Announces Collaboration with Rheonix, Inc. on Genotyping Test for Warfarin Sensitivity
Published: Jun 21, 2011
ROCHESTER, Minn.--(BUSINESS WIRE)--Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The genotyping test will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. Additionally, the test will be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories, to clients throughout the world.